MedTrace Logo

Development of a mHealth Intervention for Ambivalent Smokers

NCT04560868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2023-01-23

Study results available
· View outcomes & findings →

Summary

The current pilot study will assess the feasibility and acceptability of a novel mHealth app designed for people who are ambivalent about quitting smoking. Results will be used to refine the intervention and plan for a future randomized effectiveness trial.

Conditions

  • Tobacco Use Disorder
  • Smoking Cessation
  • Motivation
  • Behavior, Smoking

Interventions

DEVICE

Control mHealth program

The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.

DEVICE

Experimental mHealth program

The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.

DRUG

Nicotine patch

Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Jennifer McClure, PhD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-16
Primary Completion
2021-09-27
Completion
2021-09-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04560868 on ClinicalTrials.gov